Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon in Two-Year Deal to Provide Immunex with Knockout Models

NEW YORK, July 31 – Lexicon Genetics of The Woodlands, Texas, said Tuesday it had signed a two-year deal to provide Immunex with knockout mammalian models for the pharmaceutical company’s drug development program.

In exchange, Lexicon will receive an up-front technology access fee, annual research funding, and milestone and royalty payments on products developed through the collaboration.

Lexicon did not disclose the specific financial terms of the deal.

"Our gene discovery tools have defined a number of candidate molecular targets for therapeutics," Thomas Daniel, Immunex’s senior vice president for discovery research, said in a statement.

"This collaboration with Lexicon provides a valuable approach for us to prioritize the most important of these targets through in vivo validation," he said.

The deal follows a January agreement in which Lexicon gave Immunex a multi-year, non-exclusive sublicense for the use of its patented gene targeting technology.

Lexicon receives annual license fees, as well as technology usage fees for each model developed by Immunex using the company’s gene targeting technologies. In addition, Lexicon may receive milestone payments on products stemming from Lexicon's technologies.

Lexicon has 14 sublicensees for its gene targeting technologies.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.